Relapsing Multiple Sclerosis Clinical Trials

116 clinical trials for Relapsing Multiple Sclerosis across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) — RECRUITING · PHASE3
• A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) — RECRUITING · PHASE2
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — RECRUITING · PHASE3
• An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis — RECRUITING · PHASE1
• A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis — RECRUITING
• A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk — RECRUITING
• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — RECRUITING
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — RECRUITING · PHASE3
• Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis — RECRUITING · PHASE2
• ROAD: Retrospective Analysis of Ocrelizumab Use in Older Adults: A Real-World Data Analysis — RECRUITING
• Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study — RECRUITING
• An open-label, multi-center, phase 1/2 study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with Relapsing Multiple Sclerosis with breakthrough disease activity during previous treatment with a highly efficacious therapy — RECRUITING · PHASE2
• A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Relapsing Multiple Sclerosis — RECRUITING · PHASE2
• Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study — RECRUITING
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — RECRUITING · PHASE3
• Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod — RECRUITING · PHASE4
• Multicenter, open-label, 12 weeks Phase IV study to assess adherence to treatment in relapsing multiple sclerosis (RMS) subjects switching from other injectable DMDs using ReBiSmart to self-inject Rebif New Formulation (RNF) In a multi-dose cartriDGE (BRIDGE) — COMPLETED · PHASE4
• Efficacy and safety of AIN457 to treat patients with relapsing multiple sclerosis — TERMINATED · PHASE2
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — ACTIVE_NOT_RECRUITING · PHASE3
• P3-IMU-838-RMS-01 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-1) — TERMINATED · PHASE3
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis — COMPLETED · PHASE3
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis — NOT_YET_RECRUITING · PHASE1
• An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS) — TERMINATED · PHASE3
• Characterizing the Use of Ofatumumab in a Real World Setting — COMPLETED
• P3-IMU-838-RMS-02 - A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2) — TERMINATED · PHASE3
• A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS — TERMINATED · PHASE3
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) — ACTIVE_NOT_RECRUITING · PHASE3
• An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis — ACTIVE_NOT_RECRUITING · PHASE3
• An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis — TERMINATED · PHASE3
• A Phase III Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple Sclerosis — TERMINATED · PHASE3
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis — ACTIVE_NOT_RECRUITING · PHASE4
• Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) — TERMINATED · PHASE3
• RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis — WITHDRAWN · PHASE1
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — ACTIVE_NOT_RECRUITING · PHASE3
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — ACTIVE_NOT_RECRUITING · PHASE3
• Effects of Ocrevus in Relapsing Multiple Sclerosis — ACTIVE_NOT_RECRUITING · PHASE4
• A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis — TERMINATED · PHASE2
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) — ACTIVE_NOT_RECRUITING · PHASE3
• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis — ACTIVE_NOT_RECRUITING · PHASE3
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — ACTIVE_NOT_RECRUITING · PHASE3
• A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis — TERMINATED · PHASE3
• A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib — TERMINATED · PHASE3
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab — COMPLETED · PHASE3
• A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. — ACTIVE_NOT_RECRUITING · PHASE3
• 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis — COMPLETED · PHASE3
• Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset — ACTIVE_NOT_RECRUITING · PHASE4
• Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients — COMPLETED · PHASE4
• A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis — COMPLETED · PHASE3

Refine this search